Skip to main content
Top
Published in: Acta Diabetologica 5/2013

01-10-2013 | Original Article

Prevalence of phonatory symptoms in patients with type 2 diabetes mellitus

Authors: Abdul-Latif Hamdan, Zeina Kurban, Sami T. Azar

Published in: Acta Diabetologica | Issue 5/2013

Login to get access

Abstract

To look at the prevalence of phonatory symptoms in patients with type 2 diabetes mellitus. The correlation between these symptoms with duration of the disease, glycemic control, and neuropathy will be described. A total of 105 consecutive patients diagnosed with type 2 diabetes mellitus by their primary endocrinologist were evaluated. A control group consisting of 33 healthy subjects was recruited for this study. Demographic data included: age, gender, allergy, smoking, duration of the disease, glycemic control, and presence or absence of neuropathy. Subjects were also asked about the presence or absence of the following symptoms: hoarseness, vocal tiring or fatigue, vocal straining, and aphonia or complete loss of voice. Patients were also asked to fill out the Voice Handicap Index 10. The mean age of patients with diabetes was 53.21 + 9.68 years with male-to-female ratio of 2/3. The most common phonatory symptoms were vocal tiring or fatigue and hoarseness (34.3 and 33.3 %). There was a significant difference in the prevalence of hoarseness and vocal straining (p value 0.045 and 0.015, respectively) compared to controls. There was a significant correlation between glycemic control, neuropathy, and hoarseness (p value 0.030 and 0.001, respectively). Vocal straining and aphonia also correlated significantly with the presence of neuropathy. Close to 16 % of diabetic patients had a VHI-10 above or equal to 7. Diabetic patients are more likely to have phonatory symptoms compared to controls, namely straining and hoarseness. One out of seven patients with diabetes has reported that phonatory symptoms had a significant impact on their quality of life. The presence of neuropathy and poor glycemic control should alert the treating physician to these vocal complaints.
Literature
2.
go back to reference Gat-Yablonski G, Shalitin S, Phillip M (2006) Maturity onset diabetes of the young—review. Pediatr Endocrinol Rev 3(Suppl 3):514–520PubMed Gat-Yablonski G, Shalitin S, Phillip M (2006) Maturity onset diabetes of the young—review. Pediatr Endocrinol Rev 3(Suppl 3):514–520PubMed
3.
go back to reference Holmkvist J, Almgren P, Lyssenko V et al (2008) Common variants in maturity-onset diabetes of the young genes and future risk of type 2 diabetes. Diabetes 57(6):1738–1744PubMedCrossRef Holmkvist J, Almgren P, Lyssenko V et al (2008) Common variants in maturity-onset diabetes of the young genes and future risk of type 2 diabetes. Diabetes 57(6):1738–1744PubMedCrossRef
4.
go back to reference WHO Expert Consultation (2004) Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363(9403):157–163 WHO Expert Consultation (2004) Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363(9403):157–163
5.
go back to reference Dabelea D, Pettitt DJ, Hanson RL et al (1999) Birth weight, type 2 diabetes, and insulin resistance in Pima Indian children and young adults. Diabetes Care 22(6):944–950PubMedCrossRef Dabelea D, Pettitt DJ, Hanson RL et al (1999) Birth weight, type 2 diabetes, and insulin resistance in Pima Indian children and young adults. Diabetes Care 22(6):944–950PubMedCrossRef
6.
go back to reference Yarbrough DE, Barrett-Connor E, Kritz-Silverstein D (1998) Birth weight, adult weight, and girth as predictors of the metabolic syndrome in postmenopausal women: the Rancho Bernardo Study. Diabetes Care 21(10):1652–1658PubMedCrossRef Yarbrough DE, Barrett-Connor E, Kritz-Silverstein D (1998) Birth weight, adult weight, and girth as predictors of the metabolic syndrome in postmenopausal women: the Rancho Bernardo Study. Diabetes Care 21(10):1652–1658PubMedCrossRef
10.
go back to reference Stern MP (1996) Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents? Ann Intern Med 124(1 Pt 2):110–116PubMedCrossRef Stern MP (1996) Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents? Ann Intern Med 124(1 Pt 2):110–116PubMedCrossRef
11.
go back to reference Haffner SM, D’Agostino R Jr, Mykkanen L et al (1999) Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the insulin resistance atherosclerosis study. Diabetes Care 22(4):562–568PubMedCrossRef Haffner SM, D’Agostino R Jr, Mykkanen L et al (1999) Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the insulin resistance atherosclerosis study. Diabetes Care 22(4):562–568PubMedCrossRef
12.
go back to reference Asad A, Hameed MA, Khan UA, Ahmed N, Butt MU (2010) Reliability of the neurological scores for assessment of sensorimotor neuropathy in type 2 diabetics. J Pak Med Assoc 60(3):166–170PubMed Asad A, Hameed MA, Khan UA, Ahmed N, Butt MU (2010) Reliability of the neurological scores for assessment of sensorimotor neuropathy in type 2 diabetics. J Pak Med Assoc 60(3):166–170PubMed
13.
go back to reference Van Acker K, Bouhassira D, De Bacquer D, Weiss S, Matthys K, Raemen H, Mathieu C, Colin IM (2009) Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab 35(3):206–213 Van Acker K, Bouhassira D, De Bacquer D, Weiss S, Matthys K, Raemen H, Mathieu C, Colin IM (2009) Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab 35(3):206–213
14.
go back to reference Lewko J, Polityńska B, Kochanowicz J, Zarzycki W, Okruszko A, Sierakowska M, Jankowiak B, Górska M, Krajewska-Kułak E, Kowalczuk K (2007) Quality of life and its relationship to the degree of illness acceptance in patients with diabetes and peripheral diabetic neuropathy. Adv Med Sci 52(Suppl 1):144–146PubMed Lewko J, Polityńska B, Kochanowicz J, Zarzycki W, Okruszko A, Sierakowska M, Jankowiak B, Górska M, Krajewska-Kułak E, Kowalczuk K (2007) Quality of life and its relationship to the degree of illness acceptance in patients with diabetes and peripheral diabetic neuropathy. Adv Med Sci 52(Suppl 1):144–146PubMed
15.
go back to reference Campbell NR, Gilbert RE, Leiter LA, Larochelle P, Tobe S, Chockalingam A, Ward R, Morris D, Tsuyuki RT, Harris SB (2011) Hypertension in people with type 2 diabetes: update on pharmacologic management. Can Fam Physician 57(9):997–1002PubMed Campbell NR, Gilbert RE, Leiter LA, Larochelle P, Tobe S, Chockalingam A, Ward R, Morris D, Tsuyuki RT, Harris SB (2011) Hypertension in people with type 2 diabetes: update on pharmacologic management. Can Fam Physician 57(9):997–1002PubMed
16.
go back to reference Rosen CA, Lee AS, Osborn J, Zullo T, Murry T (2004) Development and validation of the Voice Handicap Index-10. Laryngoscope 114:1549–1556PubMedCrossRef Rosen CA, Lee AS, Osborn J, Zullo T, Murry T (2004) Development and validation of the Voice Handicap Index-10. Laryngoscope 114:1549–1556PubMedCrossRef
17.
go back to reference Jackbson BH, Johnson A, Crywalski C (1997) The Voice Handicap Index (VHI): development and validation. Am J Speech Lang Pathol 6:66–70 Jackbson BH, Johnson A, Crywalski C (1997) The Voice Handicap Index (VHI): development and validation. Am J Speech Lang Pathol 6:66–70
18.
go back to reference Arffa RE, Krishna P, Gartner-Schmidt J, Rosen CA (2011) Normative values for the Voice Handicap Index-10. J Voice. 2011 August 3. [Epub ahead of print] Arffa RE, Krishna P, Gartner-Schmidt J, Rosen CA (2011) Normative values for the Voice Handicap Index-10. J Voice. 2011 August 3. [Epub ahead of print]
19.
go back to reference Soe K, Sacerdote A, Karam J, Bahtiyar G (2011) Management of type 2 diabetes mellitus in the elderly. Maturitas 70(2):151–159 Soe K, Sacerdote A, Karam J, Bahtiyar G (2011) Management of type 2 diabetes mellitus in the elderly. Maturitas 70(2):151–159
20.
go back to reference National Eye Institute (2009) Diabetic eye disease FAQ: prevention & treatment. National Eye Institute. Accessed April 6, 2009 National Eye Institute (2009) Diabetic eye disease FAQ: prevention & treatment. National Eye Institute. Accessed April 6, 2009
21.
go back to reference Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26(Suppl) 1:S5–20 Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26(Suppl) 1:S5–20
22.
go back to reference Sataloff RT (1998) Vocal health and pedagogy chapter 19. Singular Publishing Group Inc, pp 97–106 Sataloff RT (1998) Vocal health and pedagogy chapter 19. Singular Publishing Group Inc, pp 97–106
23.
go back to reference Krishnan JA, Glick S, Smith LJ (2010) Systematic review of the association between lung function and type 2 diabetes mellitus. Diabetes Med 27(9):977–987 Krishnan JA, Glick S, Smith LJ (2010) Systematic review of the association between lung function and type 2 diabetes mellitus. Diabetes Med 27(9):977–987
24.
go back to reference Welham NV, Maclagan MA (2003) Vocal fatigue: current knowledge and future directions. J Voice 17(1):21–30; Review. PubMed PMID: 12705816 Welham NV, Maclagan MA (2003) Vocal fatigue: current knowledge and future directions. J Voice 17(1):21–30; Review. PubMed PMID: 12705816
25.
go back to reference Ijzerman TH, Schaper NC, Melai T, Blijham P, Meijer K, Willems PJ, Savelberg HH (2011) Motor nerve decline does not underlie muscle weakness in type 2 diabetic neuropathy. Muscle Nerve 44(2):241–245. doi:10.1002/mus.22039 Ijzerman TH, Schaper NC, Melai T, Blijham P, Meijer K, Willems PJ, Savelberg HH (2011) Motor nerve decline does not underlie muscle weakness in type 2 diabetic neuropathy. Muscle Nerve 44(2):241–245. doi:10.​1002/​mus.​22039
26.
go back to reference van Sloten TT, Savelberg HH, Duimel-Peeters IG, Meijer K, Henry RM, Stehouwer CD, Schaper NC (2011) Peripheral neuropathy, decreased muscle strength and obesity are strongly associated with walking in persons with type 2 diabetes without manifest mobility limitations. Diabetes Res Clin Pract 91(1):32–39 van Sloten TT, Savelberg HH, Duimel-Peeters IG, Meijer K, Henry RM, Stehouwer CD, Schaper NC (2011) Peripheral neuropathy, decreased muscle strength and obesity are strongly associated with walking in persons with type 2 diabetes without manifest mobility limitations. Diabetes Res Clin Pract 91(1):32–39
27.
go back to reference Van Acker K, Bouhassira D, De Bacquer D, Weiss S, Matthys K, Raemen H, Mathieu C, Colin IM (2009) Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics Diabetes Metab 35(3):206–213 Van Acker K, Bouhassira D, De Bacquer D, Weiss S, Matthys K, Raemen H, Mathieu C, Colin IM (2009) Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics Diabetes Metab 35(3):206–213
28.
go back to reference Perkins BA, Dholasania A, Buchanan RA, Bril V (2010) Short-term metabolic change is associated with improvement in measures of diabetic neuropathy: a 1-year placebo cohort analysis. Diabet Med 27(11):1271–1219. doi:10.1111/j.1464-5491.2010.03110.x Perkins BA, Dholasania A, Buchanan RA, Bril V (2010) Short-term metabolic change is associated with improvement in measures of diabetic neuropathy: a 1-year placebo cohort analysis. Diabet Med 27(11):1271–1219. doi:10.​1111/​j.​1464-5491.​2010.​03110.​x
29.
go back to reference Al-Maskari MY, Al-Shookri AO, Al-Adawi SH, Lin KG (2011) Assessment of quality of life in patients with type 2 diabetes mellitus in Oman. Saudi Med J 32(12):1285–1290PubMed Al-Maskari MY, Al-Shookri AO, Al-Adawi SH, Lin KG (2011) Assessment of quality of life in patients with type 2 diabetes mellitus in Oman. Saudi Med J 32(12):1285–1290PubMed
30.
go back to reference Schunk M, Reitmeir P, Schipf S, Völzke H, Meisinger C, Thorand B, Kluttig A, Greiser KH, Berger K, Müller G, Ellert U, Neuhauser H, Tamayo T, Rathmann W, Holle R (2011) Health-related quality of life in subjects with and without Type 2 diabetes: pooled analysis of five population-based surveys in Germany. Diabet Med. doi:10.1111/j.1464-5491.2011.03465.x. [Epub ahead of print] Schunk M, Reitmeir P, Schipf S, Völzke H, Meisinger C, Thorand B, Kluttig A, Greiser KH, Berger K, Müller G, Ellert U, Neuhauser H, Tamayo T, Rathmann W, Holle R (2011) Health-related quality of life in subjects with and without Type 2 diabetes: pooled analysis of five population-based surveys in Germany. Diabet Med. doi:10.​1111/​j.​1464-5491.​2011.​03465.​x. [Epub ahead of print]
Metadata
Title
Prevalence of phonatory symptoms in patients with type 2 diabetes mellitus
Authors
Abdul-Latif Hamdan
Zeina Kurban
Sami T. Azar
Publication date
01-10-2013
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 5/2013
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-012-0392-3

Other articles of this Issue 5/2013

Acta Diabetologica 5/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.